An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

TitleAn influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.
Publication TypeJournal Article
Year of Publication2010
AuthorsAguilar-Yáñez, José M., Portillo-Lara Roberto, Mendoza-Ochoa Gonzalo I., García-Echauri Sergio A., López-Pacheco Felipe, Bulnes-Abundis David, Salgado-Gallegos Johari, Lara-Mayorga Itzel M., Webb-Vargas Yenny, León-Angel Felipe O., Rivero-Aranda Ramón E., Oropeza-Almazán Yuriana, Ruiz-Palacios Guillermo M., Zertuche-Guerra Manuel I., DuBois Rebecca M., White Stephen W., Schultz-Cherry Stacey, Russell Charles J., and Alvarez Mario M.
JournalPLoS One
Volume5
Issue7
Paginatione11694
Date Published2010
ISSN1932-6203
KeywordsAnimals, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Escherichia coli, Ferrets, Hemagglutinins, Viral, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Protein Folding, Reverse Transcriptase Polymerase Chain Reaction
Abstract

BACKGROUND: The A/H1N1/2009 influenza pandemic made evident the need for faster and higher-yield methods for the production of influenza vaccines. Platforms based on virus culture in mammalian or insect cells are currently under investigation. Alternatively, expression of fragments of the hemagglutinin (HA) protein in prokaryotic systems can potentially be the most efficacious strategy for the manufacture of large quantities of influenza vaccine in a short period of time. Despite experimental evidence on the immunogenic potential of HA protein constructs expressed in bacteria, it is still generally accepted that glycosylation should be a requirement for vaccine efficacy.

METHODOLOGY/PRINCIPAL FINDINGS: We expressed the globular HA receptor binding domain, referred to here as HA(63-286)-RBD, of the influenza A/H1N1/2009 virus in Escherichia coli using a simple, robust and scalable process. The recombinant protein was refolded and purified from the insoluble fraction of the cellular lysate as a single species. Recombinant HA(63-286)-RBD appears to be properly folded, as shown by analytical ultracentrifugation and bio-recognition assays. It binds specifically to serum antibodies from influenza A/H1N1/2009 patients and was found to be immunogenic, to be capable of triggering the production of neutralizing antibodies, and to have protective activity in the ferret model.

CONCLUSIONS/SIGNIFICANCE: Projections based on our production/purification data indicate that this strategy could yield up to half a billion doses of vaccine per month in a medium-scale pharmaceutical production facility equipped for bacterial culture. Also, our findings demonstrate that glycosylation is not a mandatory requirement for influenza vaccine efficacy.

DOI10.1371/journal.pone.0011694
Alternate JournalPLoS ONE
PubMed ID20661476
PubMed Central IDPMC2908544
Grant ListCA21765 / CA / NCI NIH HHS / United States
HHSN266200700005C / / PHS HHS / United States